Thrombomodulin(TM) in tumor cell differentiation and periphery blood immune microenvironment in pral squamous carcinoma.
Thrombomodulin(TM) in tumor cell differentiation and periphery blood immune microenvironment in pral squamous carcinoma.
复制标题
血栓调节蛋白(TM)在普拉尔鳞状细胞癌肿瘤细胞分化和外周血免疫微环境中的作用。
DOI：
10.1016/j.clim.2018.02.011
复制
发表时间：
2018
影响因子：
8.6
通讯作者：
Zhi Wang
中科院分区：
文献类型：
--
作者：
Jingjing Song;Da Ma;Xiangqi Liu;Yichen Chen;Juan Fang;Vivian Wai Yan Lui;Sijia Zhao;Juan Xia;Bin Cheng;Zhi Wang
血栓调节蛋白（TM，也称为CD 141），作为抗凝剂，广泛表达于多种细胞类型的细胞表面，包括人血细胞以及某些免疫细胞。为了确定TM是否可以作为OSCC诊断的潜在标志物以及OSCC治疗的分子靶点，我们检测了153例口腔癌组织的口腔癌组织微阵列中TM的表达。此外，我们还分析了36例口腔鳞癌患者和36例健康供体DC上TM的表达。TM的表达采用标准免疫组织化学方法在153例口腔鳞癌患者的组织芯片上进行测定。采用流式细胞术检测36例口腔鳞癌患者和36例健康人外周血单个核细胞（PBMC）中CD141+ DC的比例。根据现有临床资料进行临床病理相关性分析。我们的结果显示，在单因素分析中，TM高表达与肿瘤细胞分化良好显著相关（P= 0.001），但与总生存期和无病生存期无关（P> 0.05）。另外，口腔鳞癌患者和健康人中均存在CD141+ DC，约占0.04%。口腔鳞癌患者PBMC中CD141+ DCs的比例与正常对照组比较差异无统计学意义（P> 0.05）。本研究提示TM的表达可能在口腔鳞癌的分化过程中起着至关重要的作用。CD141+ DCs在口腔鳞癌患者中的功能差异值得进一步研究，为未来的免疫治疗提供重要的治疗认识。
Thrombomodulin (TM, also known as CD141), which functions as an anticoagulant, is widely expressed on cell surface of a variety of cell types, including human blood cells as well as certain immune cells. To determine whether TM could be a potential marker for OSCC diagnosis as well as a molecular target for OSCC therapy, we examined the expression of TM in an oral cancer tissue microarray with 153 oral cancer tissues. Further, we also analyzed the expression of TM on DCs of 36 OSCC patients and 36 healthy donors. The expression of TM was determined using standard immunohistochemistry on a tissue microarray of 153 OSCC patients. Flow cytometric analyses were performed to determine the proportions of CD141+ DCs in the PBMC of 36 OSCC patients and 36 healthy donors. Clinicopathological correlations were performed based on the available clinical data. Our results showed that in the univariate analysis, high TM expression was significantly associated with well differentiation of tumor cells (P=.001), but not correlated with overall survival and disease-free survival (P>.05). In addition, CD141+ DCs were both present in OSCC patients and healthy donors with about 0.04%. There was no significant difference with the percentages of CD141+ DCs in the PBMC of OSCC patients and that of the normal control group (P>.05). This study indicates that TM expression might play the most critical role in the differentiation of OSCC tumors. Functional distinctions of CD141+ DCs in OSCC patients deserve further investigation to provide important therapeutic understandings for future immunotherapy.